Healthcare Services

Global Chikungunya Market to Reach $1B by 2030 at 9.1% CAGR

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Chikungunya Market Be By 2030 Compared To Its 2026 Market Size?

The chikungunya market size has exhibited robust growth over recent years. Projections indicate it will expand from $0.65 billion in 2025 to reach $0.71 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. This historical growth can be ascribed to several factors, including a rising incidence of mosquito-borne viral infections, the expansion of endemic regions influenced by climate variability, the restricted availability of approved vaccines, the prevalent reliance on symptomatic treatment methods, and ongoing public health monitoring initiatives.

The chikungunya market size is projected for significant expansion over the coming years, with expectations to reach $1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This anticipated growth during the forecast period is primarily fueled by rising investments in vaccine research, an increasing emphasis on preventive healthcare, the expansion of vector control programs, a growing demand for rapid diagnostic solutions, and enhanced global health funding directed towards emerging diseases. Furthermore, major trends anticipated in this period include the accelerated development of chikungunya vaccines, a rise in the adoption of antiviral treatment protocols, a stronger focus on early disease diagnosis, the broadening of supportive care solutions, and improved surveillance of mosquito-borne diseases.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report

What Key Drivers Are Fueling The Growth Of The Chikungunya Market?

The growing occurrence of mosquito-borne illnesses is anticipated to drive the expansion of the chikungunya market in the future. These diseases, which include chikungunya, dengue, and zika virus, are transmitted to humans through infected Aedes mosquitoes, presenting substantial worldwide public health concerns. The increasing global frequency of mosquito-borne diseases stems from factors such as climate change, urbanization, deforestation, pooling of stagnant water, insufficient vector control, increased international travel, and resistance to insecticides. Treatment for chikungunya helps patients suffering from mosquito-borne diseases by easing symptoms like fever, joint discomfort, and inflammation, thereby enhancing general comfort and movement, lowering the chance of complications, and boosting recovery via hydration, pain relief, and supportive interventions. As an illustration, the UK Health Security Agency, a government body based in the UK, reported in December 2024 that from January to June 2024, dengue cases among travelers returning to England, Wales, and Northern Ireland climbed to 473, showing a 201% rise from the 157 cases documented in the corresponding period of 2023. Consequently, the expanding global occurrence of mosquito-borne diseases is propelling the growth of the chikungunya market.

How Is Segmentation Applied In The Chikungunya Market Segment Analysis?

The chikungunya market covered in this report is segmented –

1) By Type: Antiviral Drugs, Herbal And Complementary Treatments, Supportive Care, Vaccines

2) By Product Form: Liquid Form, Powder, Solid Form

3) By Disease Stage: Acute, Chronic, Post-Infection

4) By Sales Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Supermarkets

5) By End User: Caregivers, Healthcare Professionals, Patients

Subsegments:

1) By Antiviral Drugs: Nucleoside Analogues, Protease Inhibitors

2) By Herbal And Complementary Treatments: Ayurvedic Remedies, Homeopathic Treatments, Traditional Chinese Medicine

3) By Supportive Care: Pain Relievers (NSAIDs, Acetaminophen), Fluid Therapy, Physiotherapy

4) By Vaccines: Live-Attenuated Vaccines, Inactivated Vaccines, mRNA-Based Vaccines

What Trends Are Influencing The Chikungunya Market?

Leading companies in the chikungunya market are concentrating on developing innovative vaccines to bolster immunity, prevent outbreaks, and address the escalating global health burden caused by chikungunya virus infections. A live attenuated chikungunya vaccine utilizes a weakened version of the chikungunya virus to stimulate an immune response without triggering the disease, offering long-term protection. For instance, in November 2023, Valneva SE, a France-based biotechnology firm, announced IXCHIQ, a live attenuated chikungunya vaccine that received approval from the Food and Drug Administration (FDA), a US-based government agency. This approval was granted through an accelerated pathway, based on anti-CHIKV neutralizing antibody titers, with continued approval contingent upon confirmation of clinical benefit in subsequent studies. Valneva was also awarded a Priority Review Voucher (PRV) by the FDA, which the company intends to monetize to fund its research and development programs. Ixchiq is administered as a single intramuscular injection and contains a live, weakened form of the chikungunya virus, which could induce symptoms in recipients similar to those of chikungunya disease.

Who Are The Companies Participating In The Chikungunya Market Environment?

Major companies operating in the chikungunya market are F Hoffmann-La Roche Ltd, Merck & Co Inc, Takeda Pharmaceutical Company Limited, Evotec SE, Valneva SE, Vaxart Inc, Inovio Pharmaceuticals Inc, Bharat Biotech International Limited, Moderna Inc, Emergent BioSolutions Inc, GlaxoSmithKline plc, Sanofi Pasteur, Instituto Butantan, Indian Immunologicals Limited, Zydus Lifesciences, BioNTech SE, Novavax Inc, Bavarian Nordic A S, Auro Vaccines LLC, Najit Technologies Inc, Clayton Biotechnologies Inc, Medigen Vaccine Biologics Corp

Get The Full Chikungunya Market Report:

https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report

Which Geographic Region Dominates The Chikungunya Market?

North America was the largest region in the chikungunya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chikungunya market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Chikungunya Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/chikungunya-global-market-report

Browse Through More Reports Similar to the Global Chikungunya Market 2026, By The Business Research Company

Keytruda Market Report 2026

https://www.thebusinessresearchcompany.com/report/keytruda-global-market-report

Sukuk Market Report 2026

https://www.thebusinessresearchcompany.com/report/sukuk-global-market-report

Ranibizumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795